HEAD & NECK CANCERS

Gedeptin, a novel gene therapy, is entering phase 2 clinical trials to evaluate its efficacy in treating recurrent head and neck cancer.

Replacing fluorouracil with paclitaxel in combination with pembrolizumab and carboplatin appears to be efficacious and tolerable in patients with recurrent/metastatic head and neck cancer.

The FDA has granted a fast track designation to ozuriftamab vedotin for treating recurrent/metastatic head and neck cancer that progressed after prior therapies.

A new immunotherapy combination of eftilagimod alpha and pembrolizumab shows promise in treating head and neck squamous cell carcinoma, even in patients with low PD-L1 expression.

In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

The 2-year investigator-assessed event-free survival rate in the intent-to-treat population of patients with high-risk head and neck squamous cell carcinoma was 67.4% with atezolizumab.

Frontline treatment with petosemtamab and pembrolizumab produced early clinical efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

According to findings from the phase 3 ESOPEC trial, perioperative chemotherapy given with FLOT improved overall survival in resectable esophageal cancer.

In a phase 1/2 trial of NT219 with cetuximab in patients with squamous cell carcinoma of the head and neck, safety and tolerability responses were encouraging.

The phase 2 VERSATILE-002 trial evaluating Versamune HPV with pembrolizumab met its primary end point in patients with first-line recurrent metastatic head and neck squamous cell cancer.

9MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal cancer, as well as other cancers.

Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.

The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.

The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.

Camrelizumab, nab-paclitaxel, and cisplatin showed statistically significant enhancements in pathologic complete responses in patients with resectable locally advanced esophageal squamous cell carcinoma.

The FDA approved tislelizumab alone for patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy not including a PD-1/PD-L1 inhibitor.

A fast track designation has been granted to 9MW2821 by the FDA for patients with advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

In an interview with Targeted Oncology, Ryan Carey, MD, and Rob Lee, PhD, discussed the preclinical research and the potential for lidocaine to kill certain cancer cells.

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Toripalimab in combination with gemcitabine and cisplatin, as well as toripalimab monotherapy, has been granted approval by the FDA for patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma.

Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

Two doses of CD40HVac, a therapeutic vaccine targeting dendritic cells, are being evaluated as treatment for HPV-positive oropharyngeal cancer in a phase 1/2a trial.

Patients with heavily pretreated head and neck cancer achieved an overall response rate of 24% with enfortumab vedotin in the phase 2 EV-202 study.

A coprimary end point in the phase 3 LEAP-010 study will not be met.